Psilocybin and LSD references

1. Sherwood, A.M. and T.E. Prisinzano, Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens. Expert Rev Clin Pharmacol, 2018. 11(1): p. 1-3.

2. Vollenweider, F.X. and M. Kometer, The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci, 2010. 11(9): p. 642-51.

3. Pahnke, W.N., et al., The experimental use of psychedelic (LSD) psychotherapy. Jama, 1970. 212(11): p. 1856-63.

4. Griffiths, R., et al., Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol, 2008. 22(6): p. 621-32.

5. Griffiths, R.R., et al., Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl), 2006. 187(3): p. 268-83; discussion 284-92.

6. Griffiths, R.R., et al., Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl), 2011. 218(4): p. 649-65.

7. Johnson, M., W. Richards, and R. Griffiths, Human hallucinogen research: guidelines for safety. J Psychopharmacol, 2008. 22(6): p. 603-20.

8. Fabregas, J.M., et al., Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend, 2010. 111(3): p. 257-61.

9. Gable, R.S., Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction, 2007. 102(1): p. 24-34.

10. Johnson, M.W. and R.R. Griffiths, Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 2017. 14(3): p. 734-740.

11. Grinspoon, L. and J.B. Bakalar, The psychedelic drug therapies. Curr Psychiatr Ther, 1981. 20: p. 275-83.

12. Griffiths, R.R., et al., Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016. 30(12): p. 1181-1197.

13. Ross, S., et al., Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol, 2016. 30(12): p. 1165-1180.

14. Grob, C.S., et al., Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 2011. 68(1): p. 71-8.

15. Carhart-Harris, R.L., et al., Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 2016. 3(7): p. 619-27.

16. Moreno, F.A., et al., Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry, 2006. 67(11): p. 1735-40.

17. Johnson, M.W., et al., Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol, 2014. 28(11): p. 983-92.

18. Bogenschutz, M.P., et al., Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol, 2015. 29(3): p. 289-99.

19. Schmiege, G.R., Jr., LSD AS A THERAPEUTIC TOOL. J Med Soc N J, 1963. 60: p. 203-7.

20. Sandison, R.A., Psychological aspects of the LSD treatment of the neuroses. J Ment Sci, 1954. 100(419): p. 508-15.

21. Gasser, P., et al., Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis, 2014. 202(7): p. 513-20.

22. Kast, E., LSD and the dying patient. Chic Med Sch Q, 1966. 26(2): p. 80-7.

23. Pahnke, W.N., et al., LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther, 1969. 9: p. 144-52.